ETNB vs. ELVN, ARQT, TNGX, ZNTL, SAGE, IMNM, SPRY, OPK, ALXO, and LBPH
Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Enliven Therapeutics (ELVN), Arcutis Biotherapeutics (ARQT), Tango Therapeutics (TNGX), Zentalis Pharmaceuticals (ZNTL), Sage Therapeutics (SAGE), Immunome (IMNM), ARS Pharmaceuticals (SPRY), OPKO Health (OPK), ALX Oncology (ALXO), and Longboard Pharmaceuticals (LBPH). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
Enliven Therapeutics' return on equity of -26.56% beat 89bio's return on equity.
89bio has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
In the previous week, Enliven Therapeutics had 6 more articles in the media than 89bio. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for 89bio. 89bio's average media sentiment score of 0.95 beat Enliven Therapeutics' score of 0.52 indicating that 89bio is being referred to more favorably in the media.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
89bio received 91 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 62.09% of users gave 89bio an outperform vote.
89bio currently has a consensus price target of $29.00, indicating a potential upside of 202.08%. Enliven Therapeutics has a consensus price target of $34.00, indicating a potential upside of 40.38%. Given 89bio's higher possible upside, equities analysts clearly believe 89bio is more favorable than Enliven Therapeutics.
95.1% of Enliven Therapeutics shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 45.8% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Enliven Therapeutics beats 89bio on 8 of the 15 factors compared between the two stocks.
Get 89bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
